Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T32456
(Former ID: TTDI01186)
|
|||||
Target Name |
Second phase insulin secretion (SPI secr)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Arteries/arterioles disorder [ICD-11: BD52] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | AGI-1067 | Drug Info | Phase 3 | Artery stenosis | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | AGI-1067 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. Mol Cell Endocrinol. 2010 Jul 29;323(2):246-55. | |||||
REF 2 | ClinicalTrials.gov (NCT00066898) ARISE Aggressive Reduction of Inflammation Stops Events. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.